Ken Griffin Exelixis, Inc. Transaction History

Citadel Advisors LLC

$483 Billion
Q2 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Exelixis, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 176,400 shares of EXEL stock, worth $4.73 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

176,400

Previous 128,900 36.85%

Holding current value

$4.73 Million

Previous $3.06 Million 29.59%

% of portfolio

0.0%

Previous 0.0%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$20.34 - $23.73 $2.91 Million - $3.4 Million	-143,201 Reduced 79.8%	36,254 $814,000
Q1 2024 May 15, 2024	SELL	$20.17 - $23.93 $8.98 Million - $10.7 Million	-445,193 Reduced 71.27%	179,455 $4.26 Million
Q4 2023 Feb 14, 2024	BUY	$19.25 - $24.13 $8.44 Million - $10.6 Million	438,398 Added 235.38%	624,648 $15 Million
Q3 2023 Nov 14, 2023	SELL	$19.04 - $22.74 $8.54 Million - $10.2 Million	-448,773 Reduced 70.67%	186,250 $4.07 Million
Q2 2023 Aug 14, 2023	SELL	$18.17 - $20.48 $53.9 Million - $60.8 Million	-2,967,064 Reduced 82.37%	635,023 $12.1 Million
Q1 2023 May 15, 2023	BUY	$16.3 - $19.41 $40.2 Million - $47.9 Million	2,468,177 Added 217.67%	3,602,087 $69.9 Million
Q4 2022 Feb 14, 2023	SELL	$14.96 - $17.39 $6 Million - $6.97 Million	-401,067 Reduced 26.13%	1,133,910 $18.2 Million
Q3 2022 Nov 14, 2022	SELL	$15.68 - $22.27 $2.15 Million - $3.06 Million	-137,435 Reduced 8.22%	1,534,977 $24.1 Million
Q2 2022 Aug 15, 2022	BUY	$17.44 - $23.16 $28 Million - $37.2 Million	1,607,162 Added 2463.08%	1,672,412 $34.8 Million
Q1 2022 May 16, 2022	SELL	$17.03 - $22.67 $6.92 Million - $9.21 Million	-406,300 Reduced 86.16%	65,250 $1.48 Million
Q4 2021 Feb 14, 2022	BUY	$15.84 - $21.88 $811,752 - $1.12 Million	51,247 Added 12.19%	471,550 $8.62 Million
Q3 2021 Nov 15, 2021	SELL	$16.3 - $21.14 $54.2 Million - $70.3 Million	-3,324,550 Reduced 88.78%	420,303 $8.89 Million
Q2 2021 Aug 16, 2021	BUY	$17.95 - $25.56 $1.56 Million - $2.22 Million	86,813 Added 2.37%	3,744,853 $68.2 Million
Q1 2021 May 17, 2021	BUY	$20.53 - $25.22 $72.5 Million - $89.1 Million	3,531,427 Added 2789.15%	3,658,040 $82.6 Million
Q4 2020 Feb 16, 2021	SELL	$18.39 - $24.8 $1.08 Million - $1.46 Million	-58,977 Reduced 31.78%	126,613 $2.54 Million
Q3 2020 Nov 16, 2020	SELL	$20.67 - $26.94 $39.4 Million - $51.3 Million	-1,904,766 Reduced 91.12%	185,590 $4.54 Million
Q1 2020 May 15, 2020	BUY	$14.46 - $21.8 $7.5 Million - $11.3 Million	518,402 Added 32.98%	2,090,356 $36 Million
Q4 2019 Feb 14, 2020	BUY	$15.15 - $18.89 $5.69 Million - $7.1 Million	375,644 Added 31.4%	1,571,954 $27.7 Million
Q3 2019 Nov 14, 2019	SELL	$17.68 - $22.65 $2.88 Million - $3.69 Million	-163,043 Reduced 11.99%	1,196,310 $21.2 Million
Q2 2019 Aug 14, 2019	BUY	$18.93 - $24.75 $19.5 Million - $25.4 Million	1,027,938 Added 310.17%	1,359,353 $29 Million
Q1 2019 May 15, 2019	SELL	$19.6 - $24.76 $1.86 Million - $2.35 Million	-94,780 Reduced 22.24%	331,415 $0
Q4 2018 Feb 14, 2019	SELL	$13.65 - $21.8 $16.2 Million - $25.8 Million	-1,184,929 Reduced 73.55%	426,195 $8.38 Million
Q3 2018 Nov 13, 2018	SELL	$15.87 - $22.4 $2.22 Million - $3.14 Million	-140,063 Reduced 8.0%	1,611,124 $0
Q2 2018 Aug 10, 2018	BUY	$18.56 - $22.45 $600,750 - $726,661	32,368 Added 1.88%	1,751,187 $0
Q1 2018 May 11, 2018	BUY	$22.15 - $31.89 $22.2 Million - $32 Million	1,002,822 Added 140.06%	1,718,819 $38.1 Million
Q4 2017 Feb 09, 2018	SELL	$24.23 - $30.93 $3.72 Million - $4.75 Million	-153,639 Reduced 17.67%	715,997 $21.8 Million
Q3 2017 Nov 09, 2017	BUY	$23.35 - $29.24 $20.3 Million - $25.4 Million	869,636	869,636 $21.1 Million

Others Institutions Holding EXEL

# of Institutions

460

Shares Held

240M

Call Options Held

2.04M

Put Options Held

1.29M

View Full List

About EXELIXIS, INC.

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $8.63B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

More about EXEL

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account